Search

everythinglearnresearchcommunity

for

Search:↓

Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.

Biosimilars lower costs but don't significantly improve access.

Early recognition and treatment of LPP can prevent hair loss and improve quality of life.

In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.

Cialis and Finasteride could be repurposed to treat aggressive melanoma.

A man's severe skin reaction from cancer treatment improved with early diagnosis and proper medication.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Certain medications can cause serious side effects, including skin reactions, stroke, muscle disorders, tongue swelling, hair loss in women, and liver failure.

The new drug delivery system effectively targets lung cancer cells.

The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

Activated ras can protect kidney cells from a certain substance that causes cell death.

Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.

Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.

Over 30 potential cancer prevention treatments are being tested, with some showing promise in early research.

Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Nanogels with hydrophobic modifications improve oral drug delivery for intestinal disease treatment.

5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.

5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.

JAK inhibitors effectively treat inflammatory skin diseases by targeting specific cytokine signals.

Targeted drug delivery to pancreatic beta-cells can improve type 2 diabetes treatment.

JAK inhibitors offer new hope for treating severe alopecia areata.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.

PTEN was identified as a specific marker for the skin disease cutaneous lupus erythematosus, and it helps increase the expression of harmful type I interferons.

DPK-060 in poloxamer gel effectively treats skin infections, but nanocarriers don't enhance its efficacy.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.